Intended For US Audiences Only.

You are leaving this site!

By clicking YES, you will be directed to another website. Click NO to remain on this page. Do you wish to continue to another website?


To place an order for BIVIGAM [Immune Globulin Intravenous (Human), 10% Liquid] please see information below:

ADMA Biologics
Customer Operations
5800 Park of Commerce Blvd, NW
Boca Raton, FL 33487  

Toll free: 800-458-4244, option 1 



The information contained in this guide is provided for informational purposes only and is current as of April 2023. Providers are encouraged to contact their payers for specific information as coding rules and guidelines are subject to payer discretion and should be verified by the paying entity. It is the provider’s sole responsibility to determine and submit appropriate codes, charges, and modifiers for services rendered. The information provided in this guide is subject to change without notice.

Healthcare providers make the ultimate determination as to when to use a specific product based on clinical appropriateness for a patient. Third-party payment for medical products and services is affected by numerous factors, and ADMA Biologics cannot guarantee success in obtaining insurance payments.

Download Coding Information
HCPCS Code Description
J1556 Injection, Immune Globulin (BIVIGAM) Intravenous, Non-Lyophilized (e.g., Liquid), 500 mg

Home Infusion Therapy Codea
HCPCS Code Description
S9338 Home infusion therapy, immunotherapy, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem

NDC Numbers
NDC Number to Use on All Claim Forms* Size Grams Protein Outer Package NDC Number Inner Package NDC Number
69800-6502-01 50 mL 5 69800-6502-1 69800-6502-2
69800-6503-01 100 mL 10 69800-6503-1 69800-6503-2
NDC Number to Use on All Claim Forms*
Size 50 mL
Grams Protein 5
Outer Package NDC Number 69800-6502-1
Inner Package NDC Number 69800-6502-2
Size 100 mL
Grams Protein 10
Outer Package NDC Number 69800-6503-1
Inner Package NDC Number 69800-6503-2

*For billing requiring an 11-digit NDC, add the preceding zero as shown above.


CPT® Codesb—IV Infusion
CPT Code Description
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour
96366 Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (list separately in addition to code for primary procedure)

For additional information please call 1-800-458-4244.

aCenters for Medicare and Medicaid Services (CMS). HCPCS file located at:;
bOptum® Current Procedural Coding Expert, publisher of CPT, a registered trademark of the AMA. Copyright 2022 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association.


BIVIGAM is an Immune Globulin Intravenous (Human), 10% Liquid, indicated for the treatment of patients with primary humoral immunodeficiency (PI). This includes, but is not limited to, the humoral immune defect in common variable immunodeficiency (CVID), X linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies (SCID).

Important Safety Information for BIVIGAM®


  • Thrombosis may occur with immune globulin intravenous (IGIV) products, including BIVIGAM. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, a history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.
  • Use of immunoglobulin intravenous (IVIG) products, particularly those containing sucrose, has been reported to be associated with renal dysfunction, acute renal failure, osmotic nephrosis, and death. Patients at risk of acute renal failure include those with any degree of preexisting renal insufficiency, diabetes mellitus, advanced age (above 65 years of age), volume depletion, sepsis, paraproteinemia, or receiving known nephrotoxic drugs.
  • Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. BIVIGAM does not contain sucrose.
  • For patients at risk of thrombosis, renal dysfunction, or renal failure, administer BIVIGAM at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.

Tap for important safety information for BIVIGAM